You are here: Industry Insights > HIV-1

News List

Biktarvy approved for the treatment of HIV-1 infection europeanpharmaceuticalreview
April 29, 2019
Biktarvy approved for the treatment of HIV-1 infection
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection drugs
April 17, 2019
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection.
MSD chalks up two HIV drug approvals in Europe pharmafile
December 03, 2018
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate)
Merck secures EC approval for Delstrigo and Pifeltro indications pharmaceutical-technology
November 30, 2018
The European Commission has granted approval to Merck for its indications Delstrigo and Pifeltro to treat adults with HIV-1.Delstrigo is a new once-daily......
European Commission Approves Merck’s DELSTRIGO firstwordpharma
November 29, 2018
In the United States, both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment experience, and are administered orally once daily...
Janssen unveils long-term data for HIV drug Symtuza pharmatimes
November 01, 2018
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV...
Janssen and ViiV report positive results for two drug regimen for HIV-1 pharmaceutical-technology
August 17, 2018
Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of an investigational long-acting injectable two drug regimen for the treatment of human immunodeficiency virus-1 (H
Janssen Enters Collaboration with Bavarian Nordic to Develop Vaccines Against Hepatitis B Virus and biospectrumasia
August 02, 2017
Collaboration to combine Janssen’s vaccine technologies with MVA-BN technology from Bavarian Nordic to advance potential new vaccine regimens.
Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B August 01, 2017
Danish biotechnology company Bavarian Nordic has entered an additional worldwide exclusive licence and collaboration agreement with Janssen Pharmaceuticals for the development of vaccine regimens against HIV-1 and hepatitis B.

Previous page 1 2 Next page